# HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

> **NCT03906643** · PHASE1 · WITHDRAWN · sponsor: **Herbert Lyerly**

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HS-201

## Key facts

- **NCT ID:** NCT03906643
- **Lead sponsor:** Herbert Lyerly
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-15
- **Primary completion:** 2023-01-15
- **Final completion:** 2023-02-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding exhausted
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03906643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03906643, "HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03906643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*